A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma-Reference-Cited by-同舟云学术

A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma

Published:2020-02 Issue: Volume:140 Page:87-92
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Lam Wei-Sen,Creaney Jenette,Chen Fred K.,Chin Wee Loong,Muruganandan Sanjeevan,Arunachalam Sukanya,Attia Mary S.,Read Catherine,Murray Kevin,Millward Michael,Spiro Jon,Chakera Aron,Gary Lee Y.C.^ORCID,Nowak Anna K.

Funder

Cancer Australia

icare Dust Diseases Board

Western Australian Cancer and Palliative Care network

NHMRC MRFF Career Development Fellowship

Insurance Commission of Western Australia

Miocevich Retina Fellowship

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J. Clin. Oncol.,2003

2. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial;Zalcman;Lancet,2016

3. Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option;Razak;Lung Cancer,2008

4. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma;Zauderer;Lung Cancer,2014

5. OA13.03 long-term overall survival for patients with malignant pleural mesothelioma on pembrolizumab enrolled in KEYNOTE-028;Alley;J. Thorac. Oncol.,2017

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FGF receptors mediate cellular senescence in the cystic fibrosis airway epithelium;JCI Insight;2024-06-25

2. Targeting FGFR for cancer therapy;Journal of Hematology & Oncology;2024-06-03

3. A Transformable Specific‐Responsive Peptide for One‐Step Synergistic Therapy of Bladder Cancer;Small;2024-04-25

4. Cancer drugs and diabetic retinopathy: a dangerous, underestimated association;Metabolism and Target Organ Damage;2024-01-25

5. Case report: Pemigatinib-induced retinopathy: a serial examination of subretinal fluid secondary to an FGFR inhibitor;Frontiers in Ophthalmology;2024-01-22